ACADIA Pharmaceuticals Inc.
NASDAQ:ACADBiotechnology
-$0.13 today
- Market cap
- $3.08B
- Beta
- 0.83
- P/E (TTM)
- 9.7
- EPS (TTM)
- $2.20
Volume 1.89M
Average 1.66M
ACAD Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
ACADIA Pharmaceuticals Inc.NASDAQ: ACAD
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue remains negative
Q3 FY2026 cost of revenue was $0, compared with $21.65M a year earlier. Trailing-twelve-month cost of revenue was $79.33M. Over 3 fiscal years it compounded at +106.1% a year.
Context
- Cost of revenue amounted to 8.3% of revenue in FY2025, down 0.2 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $19.83M.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 89M USD
- Year-over-year change
- +8.7%
- 4-year CAGR
- +46.8%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 89M | +8.7% |
| FY2024 | 2024-12-31 | 81.84M | +79.0% |
| FY2023 | 2023-12-31 | 45.73M | +349.8% |
| FY2022 | 2022-12-31 | 10.17M | -46.9% |
| FY2021 | 2021-12-31 | 19.14M | — |
Cost of Revenue vs competitors
How ACAD compares with its peers on the latest reported figures
- ACAD's LTM Sep 2026 cost of revenue of $79.33M is the highest of the 11 companies compared; the peer median is $787K.
- Its year-over-year change of -6.2% is the 6th highest of 7, against a peer median of +24.7%.
- Cost of revenue amounts to 6.6% of revenue for ACAD, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $79.33M | -6.2% | +106.1% | 6.6% | |
| LTM Sep 2026 | $77.55M | -68.5% | -90.3% | — | |
| LTM Jun 2026 | $52.53M | +24.5% | +109.0% | 6.8% | |
| LTM Mar 2026 | $16.42M | +24.9% | -18.7% | 7.5% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.01M | — | — | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M | +7.4% | +307.8% | 5.0% |
| LTM Mar 2026 | $574K | +69.3% | +0.2% | — | |
| LTM Mar 2026 | $284K | +67.1% | +24.6% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $82K | — | — | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $79K | — | — | — |
| LTM Dec 2025 | $0 | — | — | — | |
| Peer median (excluding ACAD) | $787K | +24.7% | +12.4% | 6.8% | |
Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 484.15M | 517.24M | 726.44M | 957.8M | 1.07B |
| Cost of Revenue | 19.14M | 10.17M | 45.73M | 81.84M | 89M |
| Gross Profit | 465M | 507.07M | 680.71M | 875.96M | 982.51M |
| Gross Margin | 96.0% | 98.0% | 93.7% | 91.5% | 91.7% |
| Research & Development | 239.42M | 361.58M | 351.62M | 303.25M | 328.8M |
| Selling, General & Admin | 396.03M | 369.09M | 402.47M | 488.43M | 548.89M |
| Operating Expenses | 635.44M | 730.67M | 754.09M | 645.16M | 877.7M |
| Depreciation & Amortization | 3.34M | 2.03M | 5.55M | 15.88M | 11.76M |
| EBITDA | (164.18M) | (211.42M) | (45.48M) | 100.16M | 150.66M |
| EBITDA Margin | -33.9% | -40.9% | -6.3% | 10.5% | 14.1% |
| Operating Income | (170.44M) | (223.6M) | (73.38M) | 230.79M | 104.81M |
| Operating Margin | -35.2% | -43.2% | -10.1% | 24.1% | 9.8% |
| Interest Income | 591K | 6.61M | 17.23M | 25.46M | 31.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.92M | 10.15M | 22.34M | 27.28M | 34.09M |
| Income Before Tax | (167.52M) | (213.44M) | (51.04M) | 258.08M | 138.9M |
| Pre-Tax Margin | -34.6% | -41.3% | -7.0% | 26.9% | 13.0% |
| Income Tax Expense | 351K | 2.53M | 10.25M | 31.62M | (252.1M) |
| Net Income | (167.87M) | (215.98M) | (61.29M) | 226.45M | 391M |
| Net Margin | -34.7% | -41.8% | -8.4% | 23.6% | 36.5% |
| EPS (Basic) | (1.05) | (1.34) | (0.37) | 1.37 | 2.32 |
| EPS (Diluted) | (1.05) | (1.34) | (0.37) | 1.36 | 2.29 |
| Weighted Avg Shares | 160.49M | 161.68M | 163.82M | 165.72M | 169.34M |
| Weighted Avg Shares (Diluted) | 160.49M | 161.68M | 163.82M | 166.36M | 171.36M |
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.